Zilucoplan Adverse Events: What the Label and Studies Report

What zilucoplan is and what it is approved for

Zilucoplan is a prescription medicine, not a supplement and not a consumer product. A 2024 review of peptide and oligonucleotide approvals described zilucoplan as a synthetic macrocyclic peptide inhibitor of complement component C5 that received United States approval in 2023 for generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive (PMID 38399458). Any use outside that labeled population is investigational. A 2025 comprehensive review of myasthenia gravis treatment options placed zilucoplan alongside other complement inhibitors and neonatal Fc receptor blockers within the targeted treatment landscape for the disease (PMID 40544117).

Understanding the adverse event profile requires understanding the mechanism. A 2023 review of complement in myasthenia gravis described how terminal complement blockade prevents formation of the membrane attack complex at the neuromuscular junction, and noted that the same blockade removes a defense the body uses against encapsulated bacteria (PMID 37869140). A 2025 review of the neuromuscular junction and the complement system covered the same biology and the therapeutic agents built around it (PMID 40675737).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any symptom, medicine or treatment decision. Nothing here describes how a medicine is prepared, dosed or administered.

Boxed warning: serious meningococcal infections

United States prescribing information for zilucoplan opens with a boxed warning for serious meningococcal infections, the most prominent safety statement the label carries. The warning reflects a class effect of terminal complement inhibition rather than a finding unique to one product. A 2022 review of complement, anti-complement therapeutics and other targeted immunotherapies in myasthenia gravis reported that inhibition at the C5 level raises susceptibility to Neisseria meningitidis and other encapsulated organisms, and that vaccination against meningococcal disease is a standard requirement before complement inhibitor therapy begins (PMID 35730504). A 2022 review of pharmacotherapy for generalized myasthenia gravis with emphasis on newer biologicals described the same meningococcal risk and the vaccination and monitoring requirements attached to complement blocking agents (PMID 35639288).

Labeling for zilucoplan in the United States also describes a restricted distribution program that exists because of this infection risk. Meningococcal infection can present with fever, headache with stiff neck, rash, confusion, severe muscle aches or light sensitivity, and labeling frames these as presentations requiring immediate medical evaluation. Questions about vaccination status, antibacterial prophylaxis and what to watch for belong with a prescribing clinician, not with an education page.

Warnings and precautions the label lists

• Serious meningococcal infections. Carried as the boxed warning and repeated in warnings and precautions, grounded in the complement blockade mechanism described in published reviews (PMID 37869140).
• Other infections caused by encapsulated bacteria. Reviews of anti-complement therapy noted that Streptococcus pneumoniae and Haemophilus influenzae type b fall into the same susceptibility category as meningococcus during terminal complement inhibition (PMID 35730504).
• Injection site reactions. Zilucoplan is given subcutaneously, and the phase 3 trial reported injection site bruising as the most frequent treatment-emergent event in both the active and placebo arms (PMID 37059508).
• Hypersensitivity reactions. Labeling for biologic and peptide therapies in this class addresses hypersensitivity, and a 2025 review of myasthenia gravis treatment options summarised tolerability considerations across the targeted agents (PMID 40544117).

Adverse reactions in the phase 3 RAISE trial: what studies report

The RAISE study, published in 2023, was a randomised, double-blind, placebo-controlled phase 3 trial in adults with acetylcholine receptor antibody positive generalized myasthenia gravis, in which 174 participants were assigned to subcutaneous zilucoplan 0.3 mg/kg once daily or placebo for 12 weeks (PMID 37059508). Researchers reported treatment-emergent adverse events in 66 of 86 participants (77 percent) in the zilucoplan group and 62 of 88 participants (70 percent) in the placebo group over the 12 week period (PMID 37059508). The most frequently reported single event in the study was injection site bruising, occurring in 14 participants (16 percent) receiving zilucoplan and 13 participants (15 percent) receiving placebo (PMID 37059508).

On the efficacy side, the same trial reported a least squares mean change in Myasthenia Gravis Activities of Daily Living score at week 12 of minus 4.39 with zilucoplan compared with minus 2.30 with placebo, a difference of minus 2.09 (PMID 37059508). Efficacy context matters when reading adverse event rates, because a 12 week controlled window with 174 participants cannot detect rare events such as individual cases of invasive meningococcal disease.

Long-term extension findings: what studies report

A 2024 interim analysis of RAISE-XT, the open-label extension in which participants from earlier zilucoplan studies continued daily subcutaneous treatment, examined long-term safety and efficacy in generalized myasthenia gravis (PMID 38638673). Researchers reported that treatment-emergent adverse events occurred in most participants during extended exposure, that injection site bruising remained among the most commonly reported events, and that the long-term profile was described as consistent with the controlled studies that preceded it (PMID 38638673). Open-label extensions lack a placebo comparator, so event rates in them cannot be separated from background disease activity, concomitant immunosuppression or ordinary illness.

A 2025 analysis of participants on long-term zilucoplan reported changes in corticosteroid and non-steroidal immunosuppressive therapy during extended treatment, including reductions in background therapy in a portion of the cohort (PMID 40504283). That matters for safety interpretation because corticosteroids and conventional immunosuppressants carry their own adverse event burden, and shifts in those medicines change the mix of events recorded during follow-up.

Reported events grouped by body system: what studies report

Comparative safety across targeted agents: what studies report

A 2024 systematic review and Bayesian network meta-analysis compared efficacy and safety across targeted drugs for generalized myasthenia gravis, placing complement inhibitors and neonatal Fc receptor antagonists in a common framework (PMID 38300476). Indirect comparisons of this kind carry well known limits: trials differ in entry criteria, background therapy, duration and how adverse events were collected, so ranking outputs are not equivalent to head to head safety data. A 2020 review of progress toward targeted immunotherapies in myasthenia gravis made a similar point about the difficulty of comparing newer agents whose trials were not designed against each other (PMID 32833750).

A 2025 narrative review of myasthenic crisis management discussed the emerging role of molecularly targeted therapies in severe disease and the monitoring considerations that accompany them (PMID 41149784). Severe disease settings add variables such as intensive care exposure and infection risk that make attribution of individual events to a single medicine harder.

Limits of what the published record can show

• Duration. The pivotal controlled window in RAISE ran 12 weeks, which is short relative to the course of a chronic autoimmune disease (PMID 37059508).
• Sample size. With 174 randomised participants, the trial was not sized to quantify rare serious events (PMID 37059508).
• Open-label design. Extension data lack a placebo arm, so background rates cannot be separated out (PMID 38638673).
• Concomitant medicines. Participants commonly continued corticosteroids or other immunosuppressants, and those agents shifted over time during long-term follow-up (PMID 40504283).
• Population. Studied populations were adults with acetylcholine receptor antibody positive generalized myasthenia gravis, matching the approved indication described in a 2024 approvals review (PMID 38399458).

Where symptom questions belong

No education page can evaluate a symptom. Fever, severe headache, neck stiffness, rash, confusion, breathing difficulty, swallowing difficulty or a change in muscle weakness are situations the labeling and published reviews treat as requiring prompt clinical assessment (PMID 35730504). Anyone prescribed zilucoplan, considering it, or experiencing anything unexpected during treatment should talk to your prescriber or seek urgent care as the situation requires. Reporting of suspected adverse reactions to national pharmacovigilance systems is how the long-term safety record continues to be built.

References

• Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study (The Lancet Neurology, 2023)
• Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study (Therapeutic Advances in Neurological Disorders, 2024)
• Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis (Journal of Neurology, 2025)
• 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest (Pharmaceuticals, 2024)
• Role of complement in myasthenia gravis (Frontiers in Neurology, 2023)
• Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis (Expert Review of Clinical Immunology, 2022)
• Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals (Drugs, 2022)
• A comprehensive review of the treatment options in myasthenia gravis (Disease-a-Month, 2025)
• The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis (CNS Drugs, 2024)
• Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review (Neurology International, 2025)
• Neuromuscular junction and the complement system (International Review of Neurobiology, 2025)
• Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies (Current Opinion in Neurology, 2020)